|
|
 |
|
Viewing report
|
|
|
|
Innovations in Cardiovascular Disease Management: Latest Surgical Procedures, Drugs and Medical Devices
Business Insights, Aug 2007, Pages: 182
Despite significant advances in prevention and treatment, cardiovascular disease remains the leading cause of death in economically advanced countries. The developing world has also begun to experience a disconcerting growth in prevalence, where the insurgence of CVD has exacerbated the risk factors associated with indigenous communicable diseases. Keeping pace with epidemiological change in both the developed and developing world constitutes the overriding challenge for industrial players, and involves successfully integrating into localised healthcare systems and reimbursement structures, in addition to remaining aligned with product demand. In the medical device, pharmaceutical and biotechnology industries, this challenge is being met with a focus on products that reduce adverse effects, improve patient outcomes and extend the range of formulations for existing indications. ‘Innovations in Cardiovascular Disease Management’ is a new report that will examine the major developments shaping the future of the cardiovascular industry. This report will analyse the future potential of new and emerging products from the medical device, pharmaceutical and biotechnology sectors, and measure their likely impact upon the existing market. The extent to which these products can stimulate the growth and development of the future market will also be assessed. Use this report to evaluate the potential of new and emerging products in the treatment of cardiovascular diseases, assess the strength of competitor pipelines and identify future market opportunities.
Some key findings from this report:
-The worldwide market for coronary stents was valued at $6.18bn
in 2006, and with a projected CAGR of 11.6%, is expected to be
valued at $13.34bn by the year 2013. Estimates show that 95.9% of
all PCI procedures in 2006 included a BMS or DES coronary stent.
-The coronary stent market is likely to be revolutionised by novel
advancements including Absorbable Metal Stent (AMS) Technologies,
novel coating technologies, gene therapy technologies, Endothelial
Progenitor Cells, nanotechnologies, drug-eluting coronary stents,
novel Estradiol containing drug-eluting stents and regenerative stents.
-Novartis’ Rasilez (aliskiren) and Exforge (valsartan/amlodipine) are
two major anti-hyperintensives set be launched in 2007. Novartis’
Tektuma was US FDA approved in early 2007, with EMEA approval for
the treatment of high blood pressure also expected later this year.
-In April 2007, Abbot Laboratories submitted an NDA to the FDA
for a fixed dose combination Niaspan (extended release niacin) and
Simvastin, whilst hoping to launch Simcor at the start of 2008.
-A total of 126 New Chemical Entities (NCE’s) are currently in
preclinical trials, including 51 in Phase I and 122 in Phase II.
Top five reasons to order your copy today:
-Identify the new and impending medical device technologies that
are set to have a major impact upon the coronary stent market.
-Discover the emerging cardiovascular drugs with greatest
potential, and learn of their anticipated launch dates and markets of
entry.
-Track the development of bioabsorbable coronary stents and
evaluate their potential influence upon the coronary stent market.
-Assess the early stage development and current status of new and
innovative embolic protection devices.
-Analyse the best performing Minimally Invasive Cardiac Surgery
(MICS) technologies, and understand their impact upon the cardiac
surgery and percutaneous coronary intervention (PCI) markets.
Key issues examined in this report...
-The world’s number one killer. CVD remains the leading cause of
death in the US, accounting for 53% of all deaths. Rising mortality
rates in Central and Eastern Europe are prompting increased concern.
-Concerns over drug-eluting stents. Clinicians are harbouring major
concerns over numerous complications associated with drug eluting
stents. Most notably, these include the onset of late-developing stent
thrombosis, allergic inflammatory reactions and non-compliance.
-Significant global PCI procedural rates. In 2005/06, Germany had
the world’s highest procedural rate with 225,000 PCI’s (2,765pmp),
compared to China’s 95,912 (73pmp) and India’s 42,123 (41pmp).
-Discontinuation of Pfizer’s Torcetrapib. The failure of the
experimental cholestorol drug has cast doubt over rival products from
within the CETP inhibitor pipeline, although Roche Holding AG are
continuing the development of R1658. It has however created a major
opportunity for the recently approved Vytorin (Inegy) and Zetia.
-Discontinuation of Astra-Zeneca’s Exanta. A substantial blow to the
anti-thrombotics pipeline, Exanta was expected to challenge Warfarin.
Your questions answered...
-Which cardiovascular disease areas will experience the most significant
expansions in prevalence over the short, medium and long-term. ?
-What are the indications for percutaneous cornary interventions (PCI),
and what are the PCI procedural volumes in major markets, including
India and China?
-Who are the biotechnology companies developing advanced
proprietary technologies and what are the trends in this market?
-Which new chemical entities are currently in pre-clinical trials for
principle disease areas such as Angina, Atherosclerosis, Arrhythmiasis,
Atrial Fibrillation, Congestive Heart Failure, Hypercholesterolemia,
Hypertension, Myocardial Infraction, and Thrombosis?
-To what extent will the introduction of both bioabsorbable and drugeluting
stents (DES) stents influence the coronary stent market?
-Which new and emerging drugs will have the largest market impact,
and when will they be launched?
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Europe Coronary Stents Market: Revival of Drug Eluting Stents to Drive Growth
US Coronary Stents Market: Revival of Drug Eluting Stents to Drive Growth
Coronary Stents - Global Strategic Business Report
Global Coronary Stent Market Report
Coronary Stents - Global Market Trends
Coronary Stents - Global Market Trends
Stakeholder Opinions: Percutaneous Coronary Intervention - Adverse Events With Drug-Eluting Stents Demand A New Safety Standard
Japan Interventional Cardiology Devices: Coronary Stents to Drive Growth
Drug Eluting Stent (DES) Clinical Trial Analysis
Coronary Stent Clinical Trial Analysis
Drug Eluting Stents – Technology & Market Forecast
U.S. Coronary Stents Markets 2007
|
|
|
|
